Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROACH: Apatinib + GD for Pulmonary Metastases of Osteosarcoma
NCT03742193Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Aug 2019
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in osteosarcoma (OS), sponsored by Ruijin Hospital. Primary endpoint: 12 months Progression-free survival rate. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT03742193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03742193.